Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients
10.1097/CD9.0000000000000014
- VernacularTitle:Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients
- Author:
Hesong ZENG
1
;
Xingwei HE
;
Wanjun LIU
;
Jing KAN
;
Liqun HE
;
Jinhe ZHAO
;
Cynthia CHEN
;
Junjie ZHANG
;
Shaoliang CHEN
Author Information
1. Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong Univerisity of Science & Technology, Wuhan 430030, China
- Publication Type:Journal Article
- Keywords:
Abidol;
Coronavirus induced disease;
Inflammation;
In-hospital death
- From:
Cardiology Discovery
2021;01(1):37-43
- CountryChina
- Language:English
-
Abstract:
Objective::Coronavirus disease 2019 (COVID-19) is a global public health crisis. There are no specific antiviral agents for the treatment of SARS-CoV-2. Information regarding the effect of Abidol on in-hospital mortality is scarce. The present study aimed to evaluate the treatment effect of Abidol for patients with COVID-19 before and after propensity score matching (PSM).Methods::This retrospective cohort study analyzed 1019 patients with confirmed COVID-19 in China from December 22, 2019 to March 13, 2020. Patients were divided to Abidol (200 mg, tid, 5-7 days, n = 788, 77.3%) and No-Abidol ( n = 231, 22.7%) groups. The primary outcome was the mortality during hospitalization. Results::Among 1019 COVID-19 patients, the age was (60.4 ± 14.5) years. Abidol-treated patients, compared with No-Abidol-treated patients, had a shorter duration from onset of symptoms to admission, less frequent renal dysfunction, lower white blood cell counts (lymphocytes <0.8) and erythrocyte sending rate, lower interleukin-6, higher platelet counts and plasma IgG and oxygen saturation, and less frequent myocardial injury. The mortality during hospitalization before PSM was 17.9% in Abidol group and 34.6% in No-Abidol (hazard ratio (HR) = 2.610, 95% confident interval (CI): 1.980-3.440), all seen in severe and critical patients. After PSM, the in-hospital death was 13.6% in Abidol and 28.6% in No-Abidol group (HR= 2.728, 95% CI: 1.598-4.659).Conclusions::Abidol-treatment results in less in-hospital death for severe and critical patients with COVID-19. Further randomized study is warranted to confirm the findings from this study.
